A $475,000 price tag for a new cancer drug: crazy or meh?

Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
Originally published on 08/31/2017 in STAT News

In an op-ed responding to the announcement of Kymriah’s launch, Anna Kaltenboeck and Dr. Peter Bach discuss the use of indication-specific pricing and outcomes-based contracting. “Two parallel features of the Novartis announcement, independent of the price of Kymriah, are harbingers of long-needed moves toward value-based pricing, an approach that directly links a drug’s price to a transparent measure of its benefit. ”

Currently, drug prices are set for treatments irrespective of patient benefit. The call for an improved pricing system based on value is gaining attention in areas such as cancer treatment and HCV treatment. Indication specific pricing (ISP) offers a potential pathway for maximizing the value of a drug across its different uses. This is particularly relevant for cancer drugs, of which 50% have more than one indication, according to an IMS analysis. Inefficiencies in pricing arise when value varies across a drug’s indications. In the article from the Journal of the American Medical Association, Dr. Peter Bach proposed to solve this issue by linking a drug’s price directly to efficacy for each of its indications. This scenario is analyzed in the table below.

A subsequent in-depth assessment by ICER highlighted practical and operational considerations for implementing ISP. A recent critique by Amitabh Chandra and Craig Garthwaite makes the case that indication-specific pricing could lead to unintended consequences, particularly in instances where a large number of patients effectively subsidizes a lower price for an indication with higher value than their own.


Key References:

Bach, Peter B. “Indication-specific pricing for cancer drugs.” JAMA 312.16 (2014): 1629-1630.

Chandra, Amitabh, and Craig Garthwaite. “The Economics of Indication-Based Drug Pricing.” New England Journal of Medicine 377.2 (2017): 103-106.

Pearson, Steven D., “Indication-Specific Pricing of Pharmaceuticals in the United States Health Care System: A Report from the 2015 ICER Membership Policy Summit.” (2016).


Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Value-Based Pricing for Drugs: Theme and Variations
A taxonomy of the features that make a payment model truly value-based.
JAMA Viewpoint 05/02/2018
Outcomes-Based Drug Contracts Do Not Move Us Closer to Value
What steps are needed to make outcomes-based contracting a value-based approach?
Morning Consult 06/21/2017
The Drugs at the Heart of Our Pricing Crisis
The US drug pricing system is broken, but not irreparable. For large-molecule biologic drugs, enter: Production Plus Profit Pricing (P-quad, pronounced like Ahab's seagoing vessel).
NYTimes 03/15/2021
Biosimilars: Market Changes do not equal policy success
Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.
Drug Pricing Lab 03/15/2021
Bottom-Up Pricing Estimate for P-quad
How much would biologic drugs cost under P-quad pricing? Two approaches to estimating fully loaded costs plus a profit (10% and 20% examined) suggest net discounts from current prices would be at least 65% to 75%
Drug Pricing Lab 03/12/2021
Modeling P-quad
The Drug Pricing Lab engaged Milliman to conduct an independent analysis of the Production Plus Profit Pricing (P-quad) policy proposal. The Milliman analysis estimates the projected spending on U.S. biologic and biosimilar drugs under a referent scenario where there is no biosimilar entry or competition, the existing ‘status quo’ scenario under the current biosimilar environment, and the Drug Pricing Lab’s P-quad policy proposal. 

This report was commissioned by Drug Pricing Lab.
Milliman 03/12/2021
Ethics of Clinical Trials to Evaluate Biosimilars
Biosimilars require extensive, expensive, and time-consuming human testing prior to market entry, a process vastly different than generics. So why are we still doing them?
MedRx IV 03/09/2021
COVID-19 Reduced Average Life Expectancy of Americans by Five Days,…
The CDC made a mistake.
STAT 02/25/2021
Instead of debating 'first-shot' vs 'set-aside' vaccine approaches, hospitals' study…
Hospitals could start studies of their own employees to answer important questions, including whether the first-shot approach has downsides when compared to the set-aside strategy.
STAT 01/04/2021
After 4 Years of Trump, Medicare and Medicaid Badly Need…
Many promising ideas won't work as expected, and that's all the more reason for CMS to evaluate how medical care is delivered to its patients.
NYTimes 12/01/2020
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Bloomberg Opinion 09/29/2020

Stay up to date on our work and news